ILCA25 in Hong Kong set to advance global liver cancer research and treatment
As the deadline for submitting abstracts for the ILCA Annual Conference looms closer, it is a timely moment to recognise the unwavering commitment of professionals engaged in liver cancer care. The challenges faced daily—long hours spent in research, complex decision-making, and the relentless pursuit of improved outcomes for patients—underscore the vital role these voices play. The upcoming #ILCA25, scheduled to take place from 19–21 November in Hong Kong, aims to create a platform for sharing invaluable insights and hard-earned lessons from clinics, hospitals, and labs worldwide.
This year’s conference builds upon the success of the ILCA Annual Conference held in Amsterdam from 7–9 September 2023. Attracting over 500 attendees from 41 countries across multiple disciplines, the event focused on the pressing issues surrounding liver cancer research and treatment. Sessions ranged from novel screening techniques to the latest developments in systemic immunotherapy, demonstrating the breadth of expertise in the current landscape of liver cancer treatment. Highlighting its commitment to sustainability, the venue, the Postilion Hotel & Convention Centre, received a Green Key Gold certification.
The ambitious scientific programme in Amsterdam centred around topics such as hepatocellular carcinoma (HCC) related to non-alcoholic steatohepatitis (NASH) and the application of advanced spatial omics technology to better understand the tumour microenvironment. These complex subjects are crucial, as understanding the nuances of liver cancer can lead to significant paradigm shifts in clinical practice and patient outcomes. With the knowledge shared during these discussions, organisations aim to push for innovative approaches in treatment options, including surgery, locoregional therapies, and targeted agents for both HCC and cholangiocarcinoma (CCA).
In June 2023, the ILCA School of Liver Cancer, hosted at The Chinese University of Hong Kong, was another prominent event designed to enhance practitioners' understanding of liver cancer. This one-day programme provided insights into the latest developments in tumour biology, clinical trials, and management strategies for liver cancer, bridging the gap between laboratory research and bedside care. The school was a valuable resource, updating healthcare professionals on topics ranging from clinical advances in HCC management to research methodologies.
Moreover, on 21 November, the ILCA will be facilitating a session on Transarterial Chemoembolization (TACE), reflecting the ongoing evolution and role of this treatment modality in managing intermediate-stage HCC. Chaired by prominent figures in the field, this session promises to deliver critical updates on ILCA’s consensus regarding TACE practices and their integration with systemic therapies.
As interest grows in these events, the ILCA’s commitment to fostering dialogue and collaboration within the liver cancer community remains steadfast. By assembling experts and practitioners committed to excellence in the field, the room for collective advancement in knowledge and practice expands, further driving improvements in patient care.
Attending the upcoming conference in Hong Kong offers professionals a unique opportunity to contribute to the dialogue surrounding advances in liver cancer treatment and care. The exchange of experiences and lessons learnt will not only promote personal growth but also enhance the overall landscape of liver cancer management, fostering a community dedicated to better health outcomes for patients worldwide.